Aligos Therapeutics (ALGS) Preferred Stock Liabilities (2019 - 2020)
Aligos Therapeutics (ALGS) reported Preferred Stock Liabilities of $81.4 million for Q3 2020, down 19.04% on a YoY basis from $100.5 million in Q4 2019, and little changed quarter-over-quarter from $81.4 million in Q2 2020.
Aligos Therapeutics (ALGS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Aligos Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $81.4 million in Q3 2020.
- For the quarter ending Q3 2020, Preferred Stock Liabilities fell 19.04% year-over-year to $81.4 million; the trailing twelve-month figure through Sep 2020 stood at $81.4 million (down 19.04% YoY), and the FY2019 full-year result was $100.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $81.4 million, roughly flat from $81.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $100.7 million in Q4 2019, with the low at $81.4 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Aligos Therapeutics | 54.72 Mn | -25.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 81.38 Mn |
| Jun 30, 2020 | 81.38 Mn |
| Mar 31, 2020 | 81.38 Mn |
| Dec 31, 2019 | 100.70 Mn |
| Sep 30, 2019 | 100.52 Mn |